Hyaluronidase: efficacy and safety of use in cosmetology

Abstract

With an increase in requests for the correction of aesthetic imperfections with dermal fillers based on hyaluronic acid, cases of adverse events and complications have become more frequent. Hyaluronic acid in the form of a dermal filler is one of the most popular procedures in aesthetic medicine and has a high safety profile. Despite the fact that hyaluronic acid is an integral part of the extracellular matrix, fillers based on it can also cause complications. The use of an antidote in the form of hyaluronidase allows you to correct possible adverse reactions such as hypercorrection, the Tyndall effect, the formation of granulomas, and the development of tissue ischemia. Hyaluronidase is widely used in all branches of medicine, including the treatment of adhesions in the body, is used in in vitro fertilization, improves the absorption of drugs into the lesion in the treatment of cancer patients, and is also successfully used in the treatment of dermatological patients. In cosmetology, the use of enzyme helps to cope with such severe phenomena as tissue ischemia due to intravascular occlusion by the drug. And the use of ultrasound diagnostics makes it possible to correct adverse events using the enzyme strictly in the focus of the filler, thereby improving the quality of the treatment.

Keywords

hyaluronidase / hyaluronic acid / correction of complications

References

[1] Girish KS, Kemparaju K, Nagaraju S, Vishwanath BS. Hyaluronidase inhibitors: a biological and therapeutic perspective. Curr Med Chem. 2009;16(18):2261–2288. doi: 10.2174/092986709788453078

[2] Girish K.S., Kemparaju K., Nagaraju S., Vishwanath B.S. Hyaluronidase inhibitors: a biological and therapeutic perspective // Curr Med Chem. 2009. Vol. 16, N 18. P. 2261–2288. doi: 10.2174/092986709788453078

[3] Cavallini M, Gazzola R, Metalla M, Vaienti L. The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers. Aesthet Surg J. 2013;33(8):1167–1174. doi: 10.1177/1090820X13511970

[4] Cavallini M., Gazzola R., Metalla M., Vaienti L. The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers // Aesthet Surg J. 2013. Vol. 33, N 8. P. 1167–1174. doi: 10.1177/1090820X13511970

[5] Kaul A, Short WD, Wang X, Keswani SG. Hyaluronidases in Human Diseases. Int J Mol Sci. 2021;22(6):3204. doi: 10.3390/ijms22063204

[6] Kaul A., Short W.D., Wang X., Keswani S.G. Hyaluronidases in Human Diseases // Int J Mol Sci. 2021. Vol. 22, N 6. P. 3204. doi: 10.3390/ijms22063204

[7] Lee A, Grummer SE, Kriegel D, Marmur E. Hyaluronidase. Dermatol Surg. 2010;36(7):1071–1077. doi: 10.1111/j.1524-4725.2010.01585.x

[8] Lee A., Grummer S.E., Kriegel D., Marmur E. Hyaluronidase // Dermatol Surg. 2010. Vol. 36, N 7. P. 1071–1077. doi: 10.1111/j.1524-4725.2010.01585.x

[9] Moharib MM, Mitra S. Alkalinized lidocaine and bupivacaine with hyaluronidase for sub-tenon’s ophthalmic block. Reg Anesth Pain Med. 2000;25(5):514–517. doi: 10.1053/rapm.2000.5664

[10] Moharib M.M., Mitra S. Alkalinized lidocaine and bupivacaine with hyaluronidase for sub-tenon’s ophthalmic block // Reg Anesth Pain Med. 2000. Vol. 25, N 5. P. 514–517. doi: 10.1053/rapm.2000.5664

[11] Bailey SH, Fagien S, Rohrich RJ. Changing role of hyaluronidase in plastic surgery. Plast Reconstr Surg. 2014;133(2):127e–132e. doi: 10.1097/PRS.0b013e3182a4c282

[12] Bailey S.H., Fagien S., Rohrich R.J. Changing role of hyaluronidase in plastic surgery // Plast Reconstr Surg. 2014. Vol. 133, N 2. P. 127e–132e. doi: 10.1097/PRS.0b013e3182a4c282

[13] Wohlrab J, Wohlrab D, Wohlrab L, et al. Use of hyaluronidase for pharmacokinetic increase in bioavailability of intracutaneously applied substances. Skin Pharmacol Physiol. 2014;27(5):276–282. doi: 10.1159/000360545

[14] Wohlrab J., Wohlrab D., Wohlrab L., et al. Use of hyaluronidase for pharmacokinetic increase in bioavailability of intracutaneously applied substances // Skin Pharmacol Physiol. 2014. Vol. 27, N 5. P. 276–282. doi: 10.1159/000360545

[15] Popkin RJ. The use of hyaluronidase by iontophoresis in the treatment of generalized scleroderma. J Invest Dermatol. 1951;16(2):97–102. doi: 10.1038/jid.1951.15

[16] Popkin R.J. The use of hyaluronidase by iontophoresis in the treatment of generalized scleroderma // J Invest Dermatol. 1951. Vol. 16, N 2. P. 97–102. doi: 10.1038/jid.1951.15

[17] Landau M. Hyaluronidase caveats in treating filler complications. Dermatol Surg. 2015;41(Suppl. 1):S347–353. doi: 10.1097/DSS.0000000000000555

[18] Landau M. Hyaluronidase caveats in treating filler complica- tions // Dermatol Surg. 2015. Vol. 41, Suppl. 1. P. S347–S353. doi: 10.1097/DSS.0000000000000555

[19] Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg. 2005;31(8 Pt 1):893–897. doi: 10.1097/00042728-200508000-00001. Erratum in: Dermatol Surg. 2008;34(1):135.

[20] Brody H.J. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement // Dermatol Surg. 2005. Vol. 31, N 8 Pt 1. P. 893–897. doi: 10.1097/00042728-200508000-00001. Erratum in: Dermatol Surg. 2008. Vol. 34, N 1. P. 135.

[21] DeLorenzi C. New high dose pulsed hyaluronidase protocol for hyaluronic acid filler vascular adverse events. Aesthet Surg J. 2017;37(7):814–825. doi: 10.1093/asj/sjw251

[22] DeLorenzi C. New high dose pulsed hyaluronidase protocol for hyaluronic acid filler vascular adverse events // Aesthet Surg J. 2017. Vol. 37, N 7. P. 814–825. doi: 10.1093/asj/sjw251

[23] Schelke LW, Decates TS, Velthuis PJ. Ultrasound to improve the safety of hyaluronic acid filler treatments. J Cosmet Dermatol. 2018;17(6):1019–1024. doi: 10.1111/jocd.12726

[24] Schelke L.W., Decates T.S., Velthuis P.J. Ultrasound to improve the safety of hyaluronic acid filler treatments // J Cosmet Dermatol. 2018. Vol. 17, N 6. P. 1019–1024. doi: 10.1111/jocd.12726

[25] Soparkar CN, Patrinely JR. Managing inflammatory reaction to restylane. Ophthalmic Plast Reconstr Surg. 2005;21(2):151–153. doi: 10.1097/01.iop.0000155853.68249.0b

[26] Soparkar C.N., Patrinely J.R. Managing inflammatory reaction to restylane // Ophthalmic Plast Reconstr Surg. 2005. Vol. 21, N 2. P. 151–153. doi: 10.1097/01.iop.0000155853.68249.0b

[27] Bravo BSF, Bianco S, Bastos JT, Carvalho RM. Hyaluronidase: What is your fear? J Cosmet Dermatol. 2021;20(10):3169–3172. doi: 10.1111/jocd.14303

[28] Bravo B.S.F., Bianco S., Bastos J.T., Carvalho R.M. Hyaluronidase: What is your fear? // J Cosmet Dermatol. 2021. Vol. 20, N 10. P. 3169–3172. doi: 10.1111/jocd.14303

[29] Wu L, Liu X, Jian X, et al. Delayed allergic hypersensitivity to hyaluronidase during the treatment of granulomatous hyaluronic acid reactions. J Cosmet Dermatol. 2018;17(6):991–995. doi: 10.1111/jocd.12461

[30] Wu L., Liu X., Jian X., et al. Delayed allergic hypersensitivity to hyaluronidase during the treatment of granulomatous hyaluronic acid reactions // J Cosmet Dermatol. 2018. Vol. 17, N 6. P. 991–995. doi: 10.1111/jocd.12461

[31] Boone DC. Hyaluronidase iontophoresis. Phys Ther. 1969;49(2):139–145. doi: 10.1093/ptj/49.2.139

[32] Boone D.C. Hyaluronidase iontophoresis // Phys Ther. 1969. Vol. 49, N 2. P. 139–145. doi: 10.1093/ptj/49.2.139

[33] Batheja P, Thakur R, Michniak B. Transdermal iontophoresis. Expert Opin Drug Deliv. 2006;3(1):127–138. doi: 10.1517/17425247.3.1.127. Erratum in: Expert Opin Drug Deliv. 2006;3(2):303.

[34] Batheja P., Thakur R., Michniak B. Transdermal iontophoresis // Expert Opin Drug Deliv. 2006. Vol. 3, N 1. P. 127–138. doi: 10.1517/17425247.3.1.127. Erratum in: Expert Opin Drug Deliv. 2006. Vol. 3, N 2. P. 303.

[35] Sloan JB, Soltani K. Iontophoresis in dermatology. A review. J Am Acad Dermatol. 1986;15(4 Pt 1):671–684. doi: 10.1016/s0190-9622(86)70223-5

[36] Sloan J.B., Soltani K. Iontophoresis in dermatology. A review // J Am Acad Dermatol. 1986. Vol. 15, N 4 Pt 1. P. 671–684. doi: 10.1016/s0190-9622(86)70223-5

[37] Talybova AP, Kruglova LS, Stenko AG. Ultraphonophoresis of enzyme drugs in treatment of postacne scars. Russian Journal of Physiotherapy, Balneology and Rehabilitation. 2017;16(5):254–256. (In Russ). doi: 10.18821/1681-3456-2017-16-5-254-256

[38] Талыбова А.П., Круглова Л.С., Стенько А.Г. Ультрафонофорез ферментативного препарата в лечении рубцов постакне // Физиотерапия, бальнеология и реабилитация. 2017. Т. 16, № 5. C. 254–256. doi: 10.18821/1681-3456-2017-16-5-254-256

[39] Ikonnikova EV, Kruglova LS. Delayed immune-inflammatory response after hyaluronic acid filler application: a clinical case. Farmateka. 2019;(8):88–91. (In Russ). doi: 10.18565/pharmateca.2019.8.88-91

[40] Иконникова Е.В., Круглова Л.С. Отсроченный иммунно-воспалительный ответ после введения филлера на основе гиалуроновой кислоты: клинический случай // Фарматека. 2019. № 8. С. 88–91. doi: 10.18565/pharmateca.2019.8.88-91

RIGHTS & PERMISSIONS

Ikonnikova E.V., Golanova O.A., Kruglova L.S.